544 656
Platinum Priority – Urothelial Cancer
Editorial by Matthew D. Galsky, John P. Sfakianos and Bart S. Ferket on pp. 555–556 of this issue
Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer
on Predicting Response and Survival after Neoadjuvant
Chemotherapy
Roland Seiler
a[10_TD$DIFF]
, b ,Hussam Al Deen Ashab
c ,Nicholas Erho
c ,Bas W.G. van Rhijn
d ,Brian Winters
e ,James Douglas
f ,Kim E. Van Kessel
g[11_TD$DIFF]
,Elisabeth E.
[2_TD$DIFF]
Fransen van de
[12_TD$DIFF]
Putte
d[3_TD$DIFF]
,[4_TD$DIFF]
Matthew Sommerlad
f ,Natalie Q. Wang
c[13_TD$DIFF]
,Voleak Choeurng
c ,Ewan A. Gibb
c ,Beatrix Palmer-Aronsten
c ,Lucia L. Lam
c ,Christine Buerki
c ,Elai Davicioni
c ,Gottfrid Sjo¨dahl
h ,Jordan Kardos
i ,Katherine A. Hoadley
i ,Seth P. Lerner
j ,David J. McConkey
k ,Woonyoung Choi
k ,William Y. Kim
i ,Bernhard Kiss
b ,George N. Thalmann
b ,Tilman Todenho¨fer
a ,Simon J. Crabb
l ,Scott North
m, Ellen C. Zwarthoff
g ,Joost L. Boormans
n ,Jonathan Wright
e ,Marc Dall’Era
o ,Michiel S. van der Heijden
d ,Peter C. Black
a , *a
Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada;
b
Department of Urology, University of Bern, Bern,
Switzerland;
c
GenomeDx Biosciences, Inc., Vancouver, British Columbia, Canada;
d
Department of Surgical Oncology, Division of Urology, Netherlands Cancer
Institute—Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands;
e
Department of Urology, University of Washington School of Medicine, Seattle,
Washington, USA;
f
Department of Urology, University Hospital of Southampton, Hampshire, UK;
g
Department of Pathology, Erasmus MC, University Medical
Center Rotterdam, Rotterdam, The Netherlands;
h
Division of Urological Research, Department of Translational Medicine, Lund University, Malmo¨, Sweden;
i
Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA;
j
Scott Department of Urologic
Oncology, Baylor College of Medicine, Houston, Texas, USA;
k
Department of Urology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA;
l
Department of Medical Oncology, University Hospital of Southampton, Hampshire, UK;
m
Cross Cancer Institute, Department of Oncology, University of
Alberta Edmonton, Alberta, Canada;
n
Department of Urology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands;
o
UC Davis
Comprehensive Cancer Center, Sacramento, California, USA
E U R O P E A N U R O L O G Y 7 2 ( 2 0 1 7 ) 5 4 4 – 5 5 4available at
www.scienced irect.comjournal homepage:
www.europeanurology.comArticle info
Article history:
Accepted March 21, 2017
Associate Editor:
James Catto
Keywords:
Bladder cancer
Neoadjuvant chemotherapy
Molecular subtypes
Response prediction
Abstract
Background:
An early report on the molecular subtyping of muscle-invasive bladder
cancer (MIBC) by gene expression suggested that response to neoadjuvant chemothera-
py (NAC) varies by subtype.
Objective:
To investigate the ability of molecular subtypes to predict pathological
downstaging and survival after NAC.
Design, setting, and participants:
Whole transcriptome profiling was performed on pre-
NAC transurethral resection specimens from 343 patients with MIBC. Samples were
classified according to four published molecular subtyping methods. We developed a
single-sample genomic subtyping classifier (GSC) to predict consensus subtypes (clau-
din-low, basal, luminal-infiltrated and luminal) with highest clinical impact in the
context of NAC. Overall survival (OS) according to subtype was analyzed and compared
with OS in 476 non-NAC cases (published datasets).
Intervention:
Gene expression analysis was used to assign subtypes.
* Corresponding author. 2775 Laurel St., Vancouver, British Columbia V5Z 1M9, Canada.
Tel. +1 604 875 4301; Fax: +1 604 875 5604.
E-mail address:
pblack@mail.ubc.ca(P.C. Black).
http://dx.doi.org/10.1016/j.eururo.2017.03.0300302-2838/
#
2017 European Association of Urology. Published by Elsevier B.V. All rights reserved.